ESAT-6-Ag85C-polyHistag Antigen Fusion is Potential as Vaccine Candidate for Tuberculosis
Abstract
BACKGROUND: BCG vaccine has been proven to be effective protection against tuberculosis (TB) meningitis and miliary TB. However, for protection against pulmonary TB, the results remains vary widely. Recombinant vaccine consisting of two immunodominant Mtb antigens ESAT-6-Ag85C-polyHistag (EAH) is currently being developed as a new TB vaccine candidate for booster. An immugonecity test for vaccine candidates is required in the initial phase to evaluate cellular immune response. This study was conducted to evaluate the cellular immune response by measuring interferon-gamma (IFN-γ) cytokines produced by T cells after ex vivo stimulation by TB EAH antigen fusion.
METHODS: Peripheral blood mononuclear cells supernatant samples were collected from 16 new pulmonary TB subjects, 17 pulmonary TB in treatment subjects, and 10 healthy subjects. Samples were tested for IFN-γ level with enzyme-linked immunosorbent assay (ELISA). Kruskal-Wallis test was used to test the differences between IFN-γ levels among three groups, and followed by post-hoc analysis using Mann Whitney.
RESULTS: The median of IFN-γ levels for new pulmonary TB, pulmonary TB in treatment, and healthy subjects were 17.09 (2.65-140.14) pg/mL, 4.36 (2.43-21.41) pg/mL, and 2.91 (2.39-3.85) pg/mL, respectively. There were significant differences of IFN-γ levels between new pulmonary TB group and pulmonary TB in treatment group (p=0.012), between new pulmonary TB group and healthy group (p=0.001), and also between pulmonary TB in treatment group and healthy group (p=0.035).
CONCLUSION: Results show that TB EAH could stimulate cell-mediated immune responses in the three groups, with the highest IFN-γ levels are found in new pulmonary TB group, suggesting a potential immunodominant antigen fusion for vaccine candidate development.
KEYWORDS: Ag85C, ESAT-6, immunogenicity test, IFN-γ, TB vaccine candidate, tuberculosis
Full Text:
PDFReferences
World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018, article.
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016; 2: 16076, CrossRef.
Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013; 17(37): 1-372, v-vi, CrossRef.
Evans TG, Schrager L, Thole J. Status of vaccine research and development of vaccines for tuberculosis. Vaccine. 2016; 34(26): 2911-4, CrossRef.
Sable SB, Kalra M, Verma I, Khuller GK. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol. 2007; 122(3): 239-51, CrossRef.
Zagmignan A, Costa ACD, Viana JL, Lima Neto LG, Monteiro CA, Gaioso Neto AG, et al. Identification of specific antibodies against the Ag85C-MPT51-HspX fusion protein (CMX) for serological screening of tuberculosis in endemic area. Expert Rev Clin Immunol. 2017; 13(8): 837-43, CrossRef.
Kumar G, Dagur PK, Singh M, Yadav VS, Dayal R, Singh HB, et al. Diagnostic potential of Ag85C in comparison to various secretory antigens for childhood tuberculosis. Scand J Immunol. 2008; 68(2): 177-83, CrossRef.
Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 2011; 8(4): 505-19, CrossRef.
World Health Organization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. Geneva: World Health Organization; 2017, article.
Erawati M, Widyastiti NS, Winarni TI, Dharmana E. b-Glucan increases IFN-γ and IL-12 production of peripheral blood mononuclear cells with/without induction of Mycobacterium tuberculosis wild-type/mutant DNA. Indones Biomed J. 2019; 11(2): 200-4, CrossRef.
Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis. 2004; 84(1-2): 93-101, CrossRef.
Hussain S, Afzal N, Javaid K, Ullah MI, Ahmad T, Saleem Uz Z. Level of interferon gamma in the blood of tuberculosis patients. Iran J Immunol. 2010; 7(4): 240-6, PMID.
Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014; 209 (Suppl 3): S100-6, CrossRef.
Nurjana MA. Faktor risiko terjadinya tuberkulosis paru usia produktif (15-49) di Indonesia. Media Litbangkes. 2015; 25(3): 163-70, article.
Adewole OO, Ota MO, Erhabor GE, Owiafe P, Oladimeji A, Obaseki D. Interferon-gamma treatment kinetics among patients with active pulmonary tuberculosis. Niger Med J. 2013; 54(6): 376-81, CrossRef.
Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One. 2009; 4(4): e5187, CrossRef.
Tedja IGAW, Nugraha J, Tambunan BA, Oetami FS. Interferon gamma and interleukin-10 levels in PBMC of active and latent tuberculosis patients as well as healthy individuals. Indones J Clinical Pathol Med Laboratory. 2018; 24(2): 122-6, CrossRef.
Wibowo RY, Tambunan BA, Nugraha J, Srioetami F, Tanoerahardjo. Ekspresi IFNγ oleh sel T CD4+ dan CD8+ setelah stimulasi antigen fusi ESAT-6-CFP-10 pada pasien tuberkulosis paru aktif. Buletin Penelitian Kesehatan. 2017; 45(4): 223-6, CrossRef.
Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala JN. T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol. 2017; 43(2): 133-41, CrossRef.
Lombardi A, Villa S, Castelli V, Bandera A, Gori A. T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous Mycobacteria infection: pathophysiology and therapeutic perspectives. Microorganisms. 2021; 9(12): 2460, CrossRef.
Yunda DK, Witjaksono F, Nurwidya F. Correlation between protein intake, fat free mass, and total lymphocyte count with quality of life in pulmonary tuberculosis patients undergoing intensive phase treatment in Pekanbaru, Riau Province. Mol Cell Biomed Sci. 2020; 4(3): 128-34, CrossRef.
DOI: https://doi.org/10.18585/inabj.v15i2.2162
Copyright (c) 2023 The Prodia Education and Research Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:





The Prodia Education and Research Institute